Add-on metformin promising in ER-positive endometrial cancer
UC Cancer Center expert comments featured in MedPage Today article
The University of Cincinnati Cancer Center's Amanda Jackson was featured in a MedPage Today article commenting on new research that found adding metformin as a combination therapy was tied to deep responses and prolonged progression-free survival in some patients with recurrent estrogen receptor (ER)-positive endometrial cancer.
All 25 patients in the RESOLVE study, led by Dana-Farber Cancer Institute, received metformin in addition to the drugs letrozole and abemaciclib.
At a median follow-up of 17 months, three patients had a complete response to the therapy, five had a partial response and 16 had stable disease. Median progression free survival was beyond 19.3 months, with no patients stopping the therapy due to toxicities.
Jackson, MD, noted multiple studies have suggested metformin can have a positive effect on progression free survival for this subset of patients.
While not effective to treat specific mutations, "metformin seems cost effective and has minimal side effects, and is probably a great option," said Jackson, a Cancer Center physician-researcher and associate professor, division chief and vice chair in the UC College of Medicine’s Department of Obstetrics & Gynecology.
Read the MedPage Today article.
Featured photo at top of hands holding a vial of metformin. Photo/Tashatuvango/iStock Photo.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.